EX-21.1 6 exh211.htm EXHIBIT 21.1
Exhibit 21.1
Subsidiaries of NeoStem, Inc.

Entity | Percentage of Ownership
NeoStem, Inc. | Parent Company
NeoStem Therapies, Inc. | 100%
Stem Cell Technologies, Inc. | 100%
Amorcyte, LLC | 100%
Progenitor Cell Therapy, LLC (PCT) | 100%
NeoStem Family Storage, LLC | 100%
Athelos Corporation (1) | 88.5%
PCT Allendale, LLC | 100%

(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of December 31, 2013, BD's ownership interest in Athelos was decreased to 11.5%, and our ownership increased to 88.5%. As a result in the change in ownership, approximately $0.3 million was transferred from additional paid in capital to non-controlling interests.